Hieu Lam

机构：Pfizer (United States)

发表论文 42 篇 · 总被引 1952 次 · h-index 11

代表论文

Discovery of a highly potent, selective, orally bioavailable inhibitor of KAT6A/B histone acetyltransferases with efficacy against KAT6A-high ER+ breast cancer (2023 · Cell chemical biology · 被引 72)
Abstract 1130: First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER+ breast cancer with KAT6A dysregulation (2021 · Cancer Research · 被引 14)
Abstract 1160: SAM competitive PRMT5 inhibitor PF06939999 demonstrates antitumor activity in splicing dysregulated NSCLC with decreased liability of drug resistance (2021 · Cancer Research · 被引 1)
Abstract 6781: First in class catalytic inhibitor of KAT2A/B demonstrates anti-tumor activity in multiple myeloma (2026 · Cancer Research)
Abstract C029: PF-07248144 – First-in-class potent, selective KAT6i in ER+HER2− breast cancer (2025 · Molecular Cancer Therapeutics)
The Importance of Keeping Emergency Ultrasound as a Key Indexed Procedure in Emergency Medicine Residency Training (2025 · Journal of the American College of Emergency Physicians Open)